Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq pulled back off highs, however,
both continue to hold trend above 21-DMA support (S&P 500: 3,625; Nasdaq: 12,170) with limited distribution.
The distribution day count stands at five and four, respectively, with one day expiring on the S&P 500 and two on
the Nasdaq next week.

Richter Gedeon

Key points from this report:

 

  • Buy Richter Gedeon (RIC.HU; RICHT HB). The stock broke out from a cup-with-handle base in heavy volume.
  • Acquisition of Evra contraceptive patch. On December 3, Richter acquired outside the U.S. marketing rights of Janssen’s Evra transdermal contraceptive for $263.5M. The addition of Evra will enable the company to offer the widest selection of family planning solutions for women.
  • Vraylar- potential blockbuster, led by label expansion. The contribution of Vraylar royalty to total pharmaceutical sales increased to 19% in Q3 2020 from 13% in Q3 2019. Vraylar is on track to achieve $1B+ revenue in 2020, with peak sales expected at $1.7B. To further extend the label, Richter initiated phase 3 study for cariprazine as an adjunctive treatment in major depressive disorder (MDD) which is a $500M incremental revenue opportunity.
  • New launches in women’s healthcare in 2021–2022. Richter is expected to launch three in-license women’s healthcare products, Eselle, Relugolix, and Oteseconazol, in 2021–2022.
  • Next catalyst: Richter is expected to announce 2020 results in February. Management raised 2020 EBIT margin guidance to 19–20% from 15–16% previously.

Market View

U.S. Market
The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq are trending into new all-time
highs after clearing out from consolidation this week. Near-term support for both indices remains this rising 10-

DMA (S&P 500: 3,642; Nasdaq: 12,215). The distribution day count declined, falling to four and three, respec-
tively, with no further expiration next week.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq are trading at all-time highs. Sup-
port remains the rising 10- and 21-DMA (S&P 500: 3,546; Nasdaq: 11,790). Each index has six distribution

days, however three expire on each next week, including one on Monday.

Market View

U.S. Market
The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq traded relatively flat on the week,
consolidating within 2% of all-time intraday highs. Both indices tagged and held 10-DMA support this week.
Support below that level remains the rising 21-DMA (S&P 500: 3,512; Nasdaq: 11,665). The distribution day
count stands at seven and six, respectively, with one day expiring on the S&P 500 next week.

Samsung Biologics

Key points from this report:

 

  • Buy Samsung Biologics (BCS.KR; 207940 KS). The stock is actionable as it builds the right side of a new base in heavy volume with an exact pivot of KRW 863K.
  • Strategic partnership for COVID-19 antibody treatment: Samsung has begun mass production of Eli Lilly’s (LLY) COVID-19 antibody drug after receiving emergency use approval from the U.S. FDA. Lilly is planning to manufacture one million doses by the end of 2020.
  • Capacity expansion. On November 18, Samsung officially began the construction of the world’s largest biopharmaceutical manufacturing facility with a capacity of 256K liters. This new plant will expand total capacity by 71% to 620K liters.
  • Global expansion. Samsung Biologics has opened its first CDO R&D center in the U.S., with an aim to expand to Europe and China in coming years.
  • Biosimilar update. The company now has five marketed biosimilars in its portfolio with two in phase 3 trials. The European Medicines Agency has accepted the filing of its Lucentis Biosimilar.
  • See other ideas in our O’Neil Health Care Weekly

Pacira BioSciences

Key points from this report:

 

  • Buy Pacira Biosciences (PCRX). The stock is actionable after breaking out of a 13-week consolidation base on above average volume. Buy at current levels or on any constructive pullback to the rising 10-DMA.
  • Strong post COVID-19 recovery. Exparel net product sales for October came in at $40.7M (+112% y/y). The drug has outpaced the elective surgery market throughout the pandemic. According to weekly data from mid-October, elective surgery procedures in the U.S. were down 26% while Exparel sales were up 13%. Management believes 90%+ of delayed procedures will be performed this year, with 2021 a substantial improvement over 2020.
  • No competition until mid-2021. The U.S. FDA has classified Heron Therapeutics’ (HRTX) application for HTX-011 as class-2 submission, which indicates the agency could take up to six months to review the new information.
  • Looking forward. The company will announce Q4 results in February. For 2020, consensus expects revenue and EPS growth of 2% and 26%, y/y, respectively. Consensus expects 2021 revenue and EPS growth of 26% and 74%, y/y, respectively
  • See other ideas in our O’Neil Health Care Weekly